Supplementary Figure 4 from MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial

• DOI: 10.1158/1078-0432.22477086.v1
• Publication Date: 2023-04-01T14:06:07Z
• Authors: Debashis Sarker; Ruth Plummer; Tim Meyer; Mikael H. Sodergren; Bristi Basu; Cheng Ean Chee; Kai-Wen Huang; Daniel H. Palmer; Yuk Ting Ma; T.R. Jeff Evans; Duncan R.C. Spalding; Madhava Pai; Rohini Sharma; David J. Pinato; James Spicer; Sarah Hunter; Vineet Kwatra; Joanna P. Nicholls; David Collin; Robert Nutbrown; Helen Glenny; Sonia Fairbairn; Vikash Reebye; Jon Voutila; Stephanie Dorman; Pinelopi Andrikakou; Peter Lloyd; Steve Felstead; Jenni Vasara; Robert Habib; Chris Wood; Pal Saetrom; Hans E. Huber; David C. Blakey; John J. Rossi; Nagy Habib
• Keywords: CEBPA; Open label

<p>A) CT and MRI of patient with prolonged partial response MTL-CEBPA treatment B) IFN-gamma, NFkB IL6 trend at days 1, 8 15 following C) AFP change from baseline to 4, 16 weeks on treatment</p>